TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36055307

Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34187524

Group type: EXPERIMENTAL
Intervention: Stereotactic EEG-guided Radiofrequency Thermocoagulation (RF-TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior Temporal Lobectomy (ATL)
Number of subjects: 0
Study: 35152961

Group type: EXPERIMENTAL
Intervention: Virtual real-time radiology consultation with referring PCPs and patients, including discussion of CT images focused on vascular atherosclerosis.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Virtual real-time radiology consultation with referring PCPs and patients.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Changes in prescriptions for statins or antihypertensive medications after consultation.
Number of subjects: 107
Study: 34847717

Group type: EXPERIMENTAL
Intervention: Wound photography for assessment of surgical site infection (SSI)
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Wound photography for assessment of wound healing
Number of subjects: 1478
Study: 35660843

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Liberal oxygen therapy
Number of subjects: 217
Study: 32696911

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endofill
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 60
Study: 35956400

Group type: EXPERIMENTAL
Intervention: Curcumin (1.5 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 35351388

Group type: EXPERIMENTAL
Intervention: Active gamma tACS (40 Hz for 20 min)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham gamma tACS
Number of subjects: 43
Study: 33028115

Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 0
Study: 36481768

Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 51
Study: 32684181

Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 48
Study: 32649485

Group type: EXPERIMENTAL
Intervention: Hydroactive dressing
Number of subjects: 450

Group type: COMPARATOR
Intervention: Adhesive tape (standard of care)
Number of subjects: 450
Study: 34465809

Group type: EXPERIMENTAL
Intervention: Transgenic overexpression of human KAL gene (KS-Tg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of recombinant human KAL (rhKAL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of rhKAL to vascular smooth muscle cells
Number of subjects: 0
Study: 32626744

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo Inspiratory Muscle Training (P-IMT)
Number of subjects: 55
Study: 34604918

Group type: COMPARATOR
Intervention: Alveolar corticotomy (AC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Piezocision (PZ)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GCF bone remodeling samples
Number of subjects: 51
Study: 32644883

Group type: EXPERIMENTAL
Intervention: Stress manipulation (Study 1a)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (Study 1b)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atomoxetine (Study 2)
Number of subjects: 120
Study: 34901039

Group type: EXPERIMENTAL
Intervention: RD1 group (15 ml of 0.375% ropivacaine plus 0.5 μg/kg DEX with 0.1 mg/kg dexamethasone)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: RD2 group (15 ml of 0.375% ropivacaine plus 1.0 μg/kg DEX with 0.1 mg/kg dexamethasone)
Number of subjects: 108

Group type: COMPARATOR
Intervention: R group (15 ml of 0.375% ropivacaine with 0.1 mg/kg dexamethasone)
Number of subjects: 108
Study: 33079403

Group type: EXPERIMENTAL
Intervention: 2% CHG-impregnated cloths
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control cloths
Number of subjects: 174
Study: 35081161

Group type: EXPERIMENTAL
Intervention: hPBL group (access to PBL modules)
Number of subjects: 53

Group type: COMPARATOR
Intervention: BL group (without access to PBL modules)
Number of subjects: 53
Study: 33767063

Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 1342
Study: 32588047

Group type: EXPERIMENTAL
Intervention: Fortified milk supplement (2 × 30 g/d) and exercise program (2 × 1 h/wk including resistance, balance, and aerobic training)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 180
Study: 35866799

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 33407133

Group type: EXPERIMENTAL
Intervention: Single-locus SSR markers
Number of subjects: 27

Group type: COMPARATOR
Intervention: Multi-locus SSR markers
Number of subjects: 27
Study: 32665372

Group type: EXPERIMENTAL
Intervention: Analysis of transmitted recorded home oximetry (RHO) data
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard monthly clinic visit assessments
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study: 34975829

Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy (OIT)
Number of subjects: 50
Study: 33171557

Group type: EXPERIMENTAL
Intervention: Real-time navigation guided implant insertion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free-hand implant insertion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Implants with length <47.5 mm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Implants with length ≥47.5 mm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proximal implant group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Distal implant group
Number of subjects: 24
Study: 36394874

Group type: EXPERIMENTAL
Intervention: Medication Optimization (MED group)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT group)
Number of subjects: 261
Study: 32865169

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (PO CYC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IV CYC)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Both PO and IV CYC
Number of subjects: 302
Study: 35378821

Group type: EXPERIMENTAL
Intervention: Shumian Capsule (SMC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 33025252

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 35658479

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 213

Group type: COMPARATOR
Intervention: Chemotherapy plus temsirolimus
Number of subjects: 213
Study: 34530857

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 0
Study: 35656222

Group type: EXPERIMENTAL
Intervention: Intervention message targeting kin care motive
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Intervention message targeting disease avoidance motive
Number of subjects: 969

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 969
Study: 35466341

Group type: EXPERIMENTAL
Intervention: Nursing care requirements for children who died in the PICU
Number of subjects: 104

Group type: COMPARATOR
Intervention: Circumstances of death (withdrawal of life-sustaining treatments, failed resuscitation, brain death)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Illness trajectory (acute, complex chronic condition, or cancer)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Length of PICU stay
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Critical care devices
Number of subjects: 104
Study: 32869589

Group type: EXPERIMENTAL
Intervention: Acupuncture at tendon blockage point of quadriceps femoris muscle belly
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sodium hyaluronate injection into articular cavity
Number of subjects: 76
Study: 36608979

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both ABMT and ACT
Number of subjects: 53
Study: 33043591

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg BID)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33968372

Group type: EXPERIMENTAL
Intervention: Sociodemographic characteristics (age, sex, education, residential location)
Number of subjects: 90551

Group type: EXPERIMENTAL
Intervention: Poor tooth brushing habit
Number of subjects: 90551

Group type: EXPERIMENTAL
Intervention: Having teeth
Number of subjects: 90551
Study: 35020465

Group type: EXPERIMENTAL
Intervention: TX-CEX (docetaxel plus capecitabine followed by cyclophosphamide, epirubicin, and capecitabine)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: T-CEF (docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 1500
Study: 33370173

Group type: EXPERIMENTAL
Intervention: Masks (general use in the community)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community mask recommendation (from 1 randomized controlled trial)
Number of subjects: 0
Study: 36193496

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal repair
Number of subjects: 130

Group type: COMPARATOR
Intervention: Tension-free hernia repair (control group)
Number of subjects: 130
Study: 32462496

Group type: EXPERIMENTAL
Intervention: Real c‐iTBS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham c‐iTBS
Number of subjects: 8
Study: 35595673

Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Conventional Transradial Access (TRA)
Number of subjects: 1307
Study: 34578917

Group type: EXPERIMENTAL
Intervention: KB290 + βC beverage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 100
Study: 36396433

Group type: EXPERIMENTAL
Intervention: IVT with MT
Number of subjects: 396

Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 396
Study: 33478501

Group type: EXPERIMENTAL
Intervention: TAT-modified serum albumin nanoparticles (TAT-TMP-NPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other treatment groups (not specified)
Number of subjects: 0
Study: 32502050

Group type: EXPERIMENTAL
Intervention: Video-guided educational intervention (13-minute captioned video clips with school engagement themes)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 46
Study: 35478070

Group type: EXPERIMENTAL
Intervention: Aniseikonia-correcting spectacle lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard spectacle lenses
Number of subjects: 0
Study: 33859214

Group type: EXPERIMENTAL
Intervention: Impulsivity-focused group intervention (IG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study: 36054211

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2298

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 2298

Group type: EXPERIMENTAL
Intervention: Lobar CAA ICH
Number of subjects: 2298

Group type: EXPERIMENTAL
Intervention: Other types of ICH
Number of subjects: 2298
Study: 34483189

Group type: EXPERIMENTAL
Intervention: Text messaging intervention offering pregnancy and childbirth support
Number of subjects: 39
Study: 35034530

Group type: EXPERIMENTAL
Intervention: 3D cues to body volume (binocular presentation)
Number of subjects: 412

Group type: COMPARATOR
Intervention: 2D cues only (monocular presentation)
Number of subjects: 412
Study: 33872045

Group type: EXPERIMENTAL
Intervention: Admission avoidance hospital at home (HAH) with comprehensive geriatric assessment (CGA)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Hospital admission with CGA
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Admission avoidance hospital at home (HAH) with CGA
Number of subjects: 1055
Study: 35717008

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) applied in 50% (n = 60) of patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 120
Study: 32119135

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (2 mg/kg before anesthesia induction and 2 mg/kg/hr during anesthesia)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (0.9% normal saline)
Number of subjects: 99
Study: 32049573

Group type: EXPERIMENTAL
Intervention: Subtotal tonsillectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Total tonsillectomy
Number of subjects: 80
Study: 36104738

Group type: EXPERIMENTAL
Intervention: 2-month choice architecture intervention (menu labelling, prompts, item positioning, feedback)
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Usual online ordering (control)
Number of subjects: 1331
Study: 33433587

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with mild disease)
Number of subjects: 0
Study: 32769888

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgical technique
Number of subjects: 0
Study: 35787230

Group type: EXPERIMENTAL
Intervention: Vicodin vignette
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Heroin vignette
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cocaine vignette
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cannabis vignette
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall characterization of substance use
Number of subjects: 216
Study: 32197029

Group type: EXPERIMENTAL
Intervention: Digital Communication Technology (DCT) tools (Text/Phone call or Email)
Number of subjects: 14978

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14978
Study: 33012118

Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 597
Study: 35072422

Group type: EXPERIMENTAL
Intervention: Endocrown
Number of subjects: 670

Group type: COMPARATOR
Intervention: Crown with post and core
Number of subjects: 670
Study: 35208580

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) on the masseter muscle
Number of subjects: 36

Group type: COMPARATOR
Intervention: Simulation of the technique (PN)
Number of subjects: 36
Study: 35941410

Group type: EXPERIMENTAL
Intervention: C-LEAR approach training
Number of subjects: 20
Study: 33899743

Group type: EXPERIMENTAL
Intervention: ‐40 mm Hg INP treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: ‐10 mm Hg INP (sham control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ‐40 mm Hg INP treatment (for patients with baseline PWD <200 m)
Number of subjects: 72

Group type: COMPARATOR
Intervention: ‐10 mm Hg INP (sham control, for patients with baseline PWD <200 m)
Number of subjects: 72
Study: 32592427

Group type: EXPERIMENTAL
Intervention: WLR ST deviation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: rST elevation
Number of subjects: 165
Study: 35915043

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Casirivimab‐imdevimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other drugs
Number of subjects: 0
Study: 36266601

Group type: EXPERIMENTAL
Intervention: CTT without augmentation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CTT augmented with Mitomycin-C (MMC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CTT augmented with Ologen implant
Number of subjects: 63
Study: 94013260

Group type: EXPERIMENTAL
Intervention: Active immunization with inactivated hepatitis A vaccine Epaxal Berna
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active/passive immunization (combination of active and passive immunization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive immunization with hepatitis A immunoglobulin preparation Globuman
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active immunization with inactivated hepatitis A vaccine Epaxal Berna (measured with IMX test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active/passive immunization (measured with IMX test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive immunization (measured with IMX test)
Number of subjects: 0
Study: 35986234

Group type: EXPERIMENTAL
Intervention: butylphthalide group: 0.2 g of butylphthalide capsules three times daily plus routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Number of subjects: 8000

Group type: COMPARATOR
Intervention: control group: routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: butylphthalide group
Number of subjects: 8000

Group type: COMPARATOR
Intervention: control group
Number of subjects: 8000
Study: 33766761

Group type: EXPERIMENTAL
Intervention: Anti-hyperglycemic drugs combined with metformin (specific drugs not detailed)
Number of subjects: 1739

Group type: EXPERIMENTAL
Intervention: Treatment regimen effects on emotional distress
Number of subjects: 1739

Group type: EXPERIMENTAL
Intervention: Validated measures of emotional distress
Number of subjects: 1739
Study: 32343483

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) only for patients
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) for patients and caregivers
Number of subjects: 510

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 510
Study: 35674827

Group type: EXPERIMENTAL
Intervention: Endurance training under hot conditions (HOT, 35 °C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endurance training under cool conditions (CON, 18 °C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (HOT and CON)
Number of subjects: 15
Study: 34365036

Group type: EXPERIMENTAL
Intervention: Postprandial plasma response after meals with varying carbohydrate (CHO) content
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postprandial plasma BCAA patterns
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postprandial plasma amino acid concentrations
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma citrulline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postprandial plasma response
Number of subjects: 10
Study: 33181890

Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 10–30 mg/kg/day; maximum 1200 mg/day
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL)
Number of subjects: 514
Study: 36054556

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 153
Study: 32514678

Group type: EXPERIMENTAL
Intervention: Periodized Circuit Training (CT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Conventional Strength Training (ST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Educational Protocol (EP)
Number of subjects: 61
Study: 34986477

Group type: EXPERIMENTAL
Intervention: Curcuminoid extract 250 mg four times a day on postoperative days 1-3
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no curcuminoids)
Number of subjects: 98
Study: 33957648

Group type: EXPERIMENTAL
Intervention: Fractionated CO2 laser treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 40
Study: 33031287

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study: 35895514

Group type: EXPERIMENTAL
Intervention: Higher concentrations (≥ median) of 2-hydroxynaphthalene, 1-hydroxyphenanthrene, summed hydroxyphenanthrenes, total summed metabolites
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Higher concentrations (≥ median) of 1-hydroxynaphthalene
Number of subjects: 358

Group type: COMPARATOR
Intervention: PAH metabolites
Number of subjects: 358
Study: 33577946

Group type: EXPERIMENTAL
Intervention: Disease-specific goals (n = 98 [51%] and n = 92 [54%])
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Function-related goals (n = 90 [48%] and n = 61 [36%])
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Knowledge goals (n = 1 [1%] and n = 17 [10%])
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Goals aligned with clinician treatment goals
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Adherence rates
Number of subjects: 190
Study: 36036838

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 600

Group type: COMPARATOR
Intervention: No-TENS
Number of subjects: 600
Study: 33274855

Group type: EXPERIMENTAL
Intervention: Naoxueshu oral liquid 10 ml three times a day for seven consecutive days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard medical management only)
Number of subjects: 120
Study: 34626579

Group type: EXPERIMENTAL
Intervention: Group-delivered Lifestyle-integrated Functional Exercise Program
Number of subjects: 309

Group type: COMPARATOR
Intervention: Individually delivered Lifestyle-integrated Functional Exercise Program
Number of subjects: 309
Study: 32197640

Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin pill (TMYX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35283011

Group type: EXPERIMENTAL
Intervention: Systematic Follow-Up (SFU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular Follow-Up (RFU)
Number of subjects: 30
Study: 34496832

Group type: EXPERIMENTAL
Intervention: Total wrist arthrodesis with CMCJ arthrodesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Total wrist arthrodesis with CMCJ preservation
Number of subjects: 120
Study: 32985080

Group type: EXPERIMENTAL
Intervention: Intervention to improve detection and treatment of depression in primary care patients receiving ART
Number of subjects: 2002